[1] RIA R,REALE A,VACCA A.Novel agents and new therapeutic approaches for treatment of multiple myeloma[J].World J Methodol,2014,4(2):73-90.
[2] VINCENT RAJKUMAR S.Multiple myeloma:2014 update on diagnosis,risk-stratification,and management[J].Am J Hematol,2014,89(10):999-1009.
[3] 包芳,吴学宾.4例 IgD型多发性骨髓瘤临床报道及文献复习[J].现代医学,2011,39(1):51-53.
[4] KELLNER J,LIU B,KANG Y,et al.Fact or fiction-identifying the elusive multiple myeloma stem cell[J].J Hematol Oncol,2013,6:91.
[5] CABALLERO O L,CHEN Y T.Cancer/testis (CT) antigens:potential targets for immunotherapy[J].Cancer Sci,2009,100(11):2014-2021.
[6] Van Der BRUGGEN P,TRAVERSARI C,CHOMEZ P,et al.A gene encoding an antigen recgnized by cytolytic T lymphocytes on a human melanoma[J].Science,1991,254(5038):1643-1647.
[7] SAHIN U,TURECI O,PFREUNDSCHUH M.Serological identification of human tumor antigens[J].Curr Opin Immunol,1997,9(5):709-716.
[8] COSTA F F,Le BLANC K,BRODIN B.Concise review:cancer/testis antigens,stem cells,and cancer[J].Stem Cells,2007,25(3):707-711.
[9] STEVENSON B J,ISELI C,PANJI S,et al.Rapid evolution of cancer/testis genes on the X chromosome[J].BMC Genomics,2007,8:129.
[10] SCANLAN M J,SIMPSON A J,OLD L J.The cancer/testis genes:review,standardization,and commentary[J].Cancer Immun,2004,4:1.
[11] HOFMANN O,CABALLERO O L,STEVENSON B J,et al.Genomewide analysis of cancer/testis gene expression[J].Proc Natl Acad Sci USA,2008,105(51):20422-20427.
[12] CHEN Y T,GURE A O,TSANG S,et al.Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library[J].Proc Natl Acad Sci USA,1998,95(12):6919-6923.
[13] LUCAS S,De SMET C,ARDEN K C,et al.Identification of a new MAGE gene with tumor-specific expression by representational difference analysis[J].Cancer Res,1998,58(4):743-752.
[14] JUNGBLUTH A A,CHEN Y T,BUSAM K J,et al.CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues[J].Int J Cancer,2002,99(6):839-845.
[15] De CARVALHO F,COSTA E T,CAMARGO A A,et al.Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines[J].PLoS One,2011,6(11):e27707.
[16] ANDRADE V C,VETTORE A L,FELIX R S,et al.Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients[J].Cancer Immun,2008,8:2.
[17] ATANACKOVIC D,LUETKENS T,HILDEBRANDT Y,et al.Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma[J].Clin Cancer Res,2009,15(4):1343-1352.
[18] CHO H J,CABALLERO O L,GNJATIC S,et al.Physical interaction of two cancer-testis antigens,MAGE-C1(CT7) and NY-ESO-1(CT6)[J].Cancer Immun,2006,6:12.
[19] TINGUELY M,JENNI B,KNIGHTS A,et al.MAGE-C1/CT-7 expression in plasma cell myeloma:sub-cellular localization impacts on clinical outcome[J].Cancer Sci,2008,99(4):720-725.
[20] JUNGBLUTH A A,ELY S,DILIBERTO M,et al.The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation[J].Blood,2005,106(1):167-174.
[21] De CARVALHO F,ALÜES V L,BRAGA W M,et al.MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy[J].Cancer Immunol Immunother,2013,62(1):191-195.
[22] ROSENZWEIG M A,LANDAU H,SELDIND,et al.Cancer-testis antigen expression and immunogenicity in AL amyloidosis[J].Blood Cancer J,2012,2:e90.
[23] CURIONI-FONTECEDRO A,NUBER N,MIHIC-PROBST D,et al.Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients[J].PLoS One,2011,6(6):e21418.
[24] ZHANG Y,BAO L,LU J,et al.The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma[J].Mol Cancer,2014,13:25.
[25] PABST C,ZUSTIN J,JACOBSEN F,et al.Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma[J].Exp Mol Pathol,2010,89(2):175-181.
[26] NUBER N,CURIONI-FONTECEDRO A,MATTERA C,et al.Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients[J].Proc Natl Acad Sci USA,2010,107(34):15187-15192.
[27] NUBER N,CURIONI-FONTECEDRO A,DANNENMANN S R,et al.MAGE-C1/CT7 spontaneously triggers a CD4+T-cell response in multiple myeloma patients[J].Leukemia,2013,27(8):1767-1769.
[28] CURIONI-FONTECEDRO A,KNIGHTS A J,TINGUELY M,et al.MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma[J].Leukemia,2008,22(8):1646-1648.
[29] LENDVAI N,GNJATIC S,RITTER E,et al.Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients[J].Cancer Immun,2010,10:4.
[30] ATANACKOVIC D,HILDEBRANDT Y,JADCZAK A,et al.Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells[J].Haematologica,2010,95(5):785-793. |
